Age (years) | Sex | Treatment duration (weeks) | Adverse reaction | CTCAE Grade | ||
---|---|---|---|---|---|---|
70 | Female | 16 | Increased CPK | 200 | IU/L | I |
66 | Female | 10 | Increased CPK | 219 | IU/L | I |
67 | Female | 40 | Increased CPK | 189 | IU/L | I |
68 | Female | 15 | Increased CPK | 200 | IU/L | I |
78 | Female | 4 | Increased CPK | 2898 | IU/L | IV |
52 | Male | 12 | Increased CPK | 321 | IU/L | I |
67 | Male | 35 | Increased CPK | 762 | IU/L | I |
36 | Male | 4 | Increased CPK | 404 | IU/L | I |
40 | Male | 10 | Increased CPK | 815 | IU/L | II |
69 | Female | 4 | Increased AST | 49 | IU/L | I |
41 | Male | 32 | Increased ALT | 42 | IU/L | I |
Increased ALP | 376 | IU/L | I | |||
Increased γ-GTP | 194 | IU/L | II | |||
65 | Male | 23 | Decreased Hb | 9.7 | g/dL | - |
85 | Female | 15 | Thrombocytopenia | 65,000 | /mL | II |